

## Azathioprine

Class: Antineoplastic Agent, Miscellaneous; Immunosuppressant Agent

### Pharmacokinetics


#### Absorption

- i.) Non-genetic
  - a. Concomitant disease states: decreased bioavailability in uremia
  - b. Formulation: oral tablet / solution for injection
- ii.) Genetic
  - a. No clear genetic factors affecting absorption

#### Distribution

- i.) Non-genetic
  - a. No clear non-genetic factors affecting distribution
- ii.) Genetic
  - a. No clear genetic factors affecting distribution

#### Metabolism



- i.) Non-genetic
  - a. Concomitant medications: TPMT or XO inhibitors
- ii.) Genetic
  - a. Genetic variation or deficiency in drug metabolizing enzyme gene(s): TPMT, XO

#### Excretion

- i.) Non-genetic
  - a. Renal impairment: delayed clearance, greater elimination half-life in end-stage renal disease, oliguria, tubular necrosis
- ii.) Genetic
  - a. No clear genetic factors affecting excretion

### Pharmacodynamics

#### Receptors

- i.) Non-genetic
  - a. No clear non-genetic factors affecting receptors
- ii.) Genetic
  - a. No clear genetic factors affecting receptors

#### Transporters

- i.) Non-genetic
  - a. No clear non-genetic factors affecting transporters
- ii.) Genetic
  - a. No clear genetic factors affecting transporters